Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jul 21:10:1179.
doi: 10.3389/fonc.2020.01179. eCollection 2020.

Comparison of Hematologic Toxicity and Bone Marrow Compensatory Response in Head and Neck vs. Cervical Cancer Patients Undergoing Chemoradiotherapy

Affiliations

Comparison of Hematologic Toxicity and Bone Marrow Compensatory Response in Head and Neck vs. Cervical Cancer Patients Undergoing Chemoradiotherapy

Lucas K Vitzthum et al. Front Oncol. .

Abstract

Background: Hematologic toxicity is a critical problem limiting treatment delivery in cancer patients undergoing concurrent chemoradiotherapy. However, the extent to which anatomic variations in radiation dose limit chemotherapy delivery is poorly understood. A unique natural experiment arises in patients with head and neck and cervical cancer, who frequently undergo identical chemotherapy but receive radiation to different regions of the body. Comparing these cohorts can help elucidate to what extent hematologic toxicity is attributable to marrow radiation as opposed to chemotherapy. Methods: In this longitudinal cohort study, we compared hematologic toxicity and bone marrow compensatory response in 148 patients (90 cervix, 58 head/neck) undergoing chemoradiotherapy with concurrent weekly cisplatin 40 mg/m2. We used linear mixed effect models to compare baseline and time-varying peripheral cell counts and hemoglobin levels between cohorts. To assess bone marrow compensatory response, we measured the change in metabolically active bone marrow (ABM) volume on 18F-fluorodeoxyglucose positron emission tomography/computed tomography. Results: We observed greater reductions in log-transformed lymphocyte, platelet, and absolute neutrophil counts (ANC) for cervix compared to head/neck cancer patients (fixed effects for time-cohort interaction [95% CI]: lymphocytes, -0.06 [-0.09, -0.031]; platelets,-0.028 [-0.051, -0.0047]; ANC, -0.043 [-0.075, -0.011]). Mean ANC nadirs were also lower for cervical vs. head/neck cancer cohorts (2.20 vs. 2.85 × 103 per μL, p < 0.01). Both cohorts exhibited reductions in ABM volume within the radiation field, and increases in ABM volume in out-of-field areas, indicating varying compensatory response to radiation injury. Conclusions: Cervical cancer patients had faster decreases in ANC, lymphocyte, and platelet counts, and lower ANC nadirs, indicating a significant effect of pelvic irradiation on acute peripheral blood cell counts. Both cohorts exhibited a compensatory response with increased out-of-field bone marrow activity.

Keywords: FDG PET; bone marrow toxicity; cervical cancer; head and neck cancer; hematologic toxicity; hematopoieisis.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Acute hematologic response during definitive chemoradiation, by disease and sex. (A) Absolute neutrophil counts (ANC); (B) lymphocyte counts; (C) hemoglobin (HGB) levels; (D) platelet counts. HNC, Head and Neck Cancer; M, Male; F, Female.
Figure 2
Figure 2
Heat map comparing changes in active bone marrow volume within skeletal sub-structures, measured by 18F-FDG PET/CT, for patients treated for cervical vs. head/neck cancer. Solid and dotted fill represent p < 0.05 and ≥0.05, respectively.

References

    1. Georgiou KR, Foster BK, Xian CJ. Damage and recovery of the bone marrow microenvironment induced by cancer chemotherapy – potential regulatory role of chemokine CXCL12/receptor CXCR4 signalling. Curr Mol Med. (2010) 10:440–53. 10.2174/156652410791608243 - DOI - PubMed
    1. Crawford J, Dale DC, Lyman GH. Chemotherapy-Induced neutropenia: risks, consequences, and new directions for its management. Cancer. (2004) 100:228–37. 10.1002/cncr.11882 - DOI - PubMed
    1. Elting LS, Rubenstein EB, Martin CG, Kurtin D, Rodriguez S, Laiho E, et al. . Incidence, cost, and outcomes of bleeding and chemotherapy dose modificaton among solid tumor patients with chemotherapy-induced thrombocytopenia. J Clin Oncol. (2001) 19:1137–46. 10.1200/JCO.2001.19.4.1137 - DOI - PubMed
    1. Abu-Rustum NR, Lee S, Correa A, Massad LS. Compliance with and acute hematologic toxic effects of chemoradiation in indigent women with cervical cancer. Gynecol Oncol. (2001) 81:88–91. 10.1006/gyno.2000.6109 - DOI - PubMed
    1. Mell LK, Sirák I, Wei L, Tarnawski R, Mahantshetty U, Yashar CM, et al. . Bone marrow-sparing intensity modulated radiation therapy with concurrent cisplatin for stage IB-IVA cervical cancer: an international multicenter phase II clinical trial (INTERTECC-2). Int J Radiat Oncol Biol Phys. (2017) 97:536–45. 10.1016/j.ijrobp.2016.11.027 - DOI - PubMed

LinkOut - more resources